citalopram + riluzole

Citalopram + riluzole is an investigational combination therapy consisting of two small molecule drugs, citalopram and riluzole. Citalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by inhibiting the reuptake of serotonin in the brain, primarily used for treating depression. Riluzole modulates glutamatergic neurotransmission and has neuroprotective properties; it is approved for amyotrophic lateral sclerosis (ALS) but has also shown antidepressant effects in preclinical and clinical studies. The combination has been studied as an adjunctive treatment for moderate-to-severe major depressive disorder (MDD), with evidence suggesting improved efficacy over citalopram alone without significant safety concerns[1][2][4].